Interacting Drugs |
Hyoscyamine, atropine, scopolamine, and phenobarbital vs Gefitinib |
Security Level |
|
Mechanism |
Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib. |
Management |
In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers. Carefully monitor clinical response and development of adverse reactions. |
Hyoscyamine, atropine, scopolamine, and phenobarbital vs Gefitinib
Post Review about Hyoscyamine, atropine, scopolamine, and phenobarbital vs Gefitinib Click here to cancel reply.
Other Interactions of Hyoscyamine, atropine, scopolamine, and phenobarbital
Other Interactions of Gefitinib
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.